Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tabimorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR known ✓ | Q92847 | 8/20 | 0.65 |
| ▸ | FCER2 | P06734 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tabimorelin SCHEMBL29440097 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| SCHEMBL6316837 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL29899698 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL209442 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL13575741 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| SCHEMBL6316843 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL7982376 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL4435323 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL22345096 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL29958795 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 553 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-4604743-A1 | FORMULATED FOOD PRODUCTS | VitaKey Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2024-10-03 | — | — | US | claimed |
| WO-2024086307-A1 | FORMULATED FOOD PRODUCTS | VITAKEY INC. (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2024086306-A1 | FORMULATED FOOD PRODUCTS | VITAKEY INC. (US) | 2024-04-25 | — | — | WO | claimed |
| US-20230330187-A1 | USE OF GHRELIN OR GHRELIN VARIANT FOR INCREASING DOSE INTENSITY OF CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH CANCER | OXEIA BIOPHARMACEUTICALS INC (US) | 2023-10-19 | — | — | US | claimed |
| WO-2023161326-A1 | COMPOUND FOR USE IN AND METHODS OF TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2023-08-31 | — | — | WO | claimed |
| US-20220370471-A1 | COMPOSITION AND METHOD FOR TREATMENT OF HIPPOCAMPAL SYNAPSE DYSFUNCTION AND COGNITIVE DEFICITS IN ALZHEIMER'S DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-24 | — | — | US | claimed |
| WO-2022226116-A1 | GHRELIN TREATMENT OF BRAIN DYSFUNCTION DUE TO VIRAL INFECTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| JP-2002521322-A | — | — | 2002-07-16 | — | — | JP | claimed |
| US-20020022649-A1 | STABLE PHARMACEUTICAL FORMULATION | HELSINN THERAPEUTICS (U.S.), INC. | 2002-02-21 | — | — | US | claimed |
| US-6281247-B1 | GLANDULAR DISORDERS; ANIMAL GROWTH REGULATORS | NOVO NORDISK A/S (DK) | 2001-08-28 | — | — | US | claimed |
| EP-1098636-A1 | A WET GRANULATION METHOD FOR PREPARING A STABLE PHARMACEUTICAL FORMULATION | NOVO NORDISK A/S (DK) | 2001-05-16 | — | — | EP | claimed |
| EP-1060190-A1 | NEW SALT FORMS OF (2E)- 5-AMINO-5- METHYLHEX-2- ENOIC ACID N-METHYL-N-((1R)-1-(N- METHYL-N-((1R)-1-(METHYLCARBAMOYL)-2- PHENYLETHYL)CARBAMOYL)-2- (2-NAPHTYL)ETHYL)AMIDE | NOVO NORDISK A/S (DK) | 2000-12-20 | — | — | EP | claimed |
| WO-2000004880-A1 | A WET GRANULATION METHOD FOR PREPARING A STABLE PHARMACEUTICAL FORMULATION | NOVO NORDISK A/S (DK) | 2000-02-03 | — | — | WO | claimed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | claimed |
| WO-1999045029-A1 | NEW SALT FORMS OF (2E)- 5-AMINO-5- METHYLHEX-2- ENOIC ACID N-METHYL-N-((1R)-1-(N- METHYL-N-((1R)-1-(METHYLCARBAMOYL)-2- PHENYLETHYL)CARBAMOYL)-2- (2-NAPHTYL)ETHYL)AMIDE | NOVO NORDISK A/S (DK) | 1999-09-10 | — | — | WO | claimed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | claimed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | IFNAR1, IFNG, IRF3 | GHSR 1226/4885FCER2 217/4885MMP9 1494/4885 |
| US-20020022649-A1 | STABLE PHARMACEUTICAL FORMULATION | GRN, COG6, UGGT1 | GHSR 617/4885FCER2 2372/4885MMP9 3352/4885 |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | BDKRB2, BDKRB1, HRH2 | GHSR 639/4885FCER2 30/4885MMP9 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.